AstraZeneca, BioInvent ink pact to evaluate BI-1206 in combo with rituximab, Calquence Ruchika Sharma12 Feb 2024 4:30 PM ISTSweden: BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...
CDSCO Panel approves Roche's PMS Study Report of Rituximab with Glucocorticoids in Wegener's Granulomatosis Dr. Divya Colin3 Dec 2023 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved a post-marketing...
Rituximab and omalizumab therapy shows promise against Bullous pemphigoid: JAMA Jacinthlyn Sylvia29 Nov 2023 5:00 AM ISTThe team led by Stephanie at the University of California Davis reported a remarkable 70% durable complete response rate in a case series of 10...
AstraZeneca Calquence approved in China for chronic lymphocytic leukaemia Ruchika Sharma5 Sept 2023 11:55 AM ISTCambridge: AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in...
Cancer chemotherapy linked to Post-COVID Pulmonary Fibrosis Jacinthlyn Sylvia11 Aug 2023 9:30 AM ISTIn the larger context of battling COVID-19, the study published in The Lancet Regional Health - Americas contributes valuable insights into the...
Dr Reddy's Labs proposed rituximab biosimilar application accepted for review by USFDA, EMA and MHRA Ruchika Sharma13 July 2023 12:02 PM ISTDRL_RI is being developed as a biosimilar of Rituxan / MabThera (rituximab), a cluster of differentiation 20 (CD20) directed cytolytic antibody.
Rituximab with mycophenolate mofetil improves symptoms in ILD patients Jacinthlyn Sylvia27 Jun 2023 9:45 AM ISTIn patients with interstitial lung disease (ILD) with an nonspecific interstitial pneumonia (NSIP) pattern, the combination of rituximab and...
USFDA nod to Roche's Polivy in combination with R-CHP for certain types of previously untreated diffuse large B-cell lymphoma Ruchika Sharma20 April 2023 2:30 PM ISTPolivy is a first-in-class anti-CD79b antibody-drug conjugate.
USFDA Committee votes in favour of clinical benefit of Roche's Polivy combination for people with previously untreated diffuse large B- cell lymphoma Ruchika Sharma13 March 2023 1:15 PM ISTPolivy is a first-in-class anti-CD79b antibody-drug conjugate.
Rituximab Treatment may significantly improve skin and lung fibrosis in Systemic Sclerosis Dr. Shravani Dali19 Feb 2023 8:00 PM ISTRituximab Treatment may significantly improve skin and lung fibrosis in Systemic Sclerosis suggests a new study published in the JAMA...
Dr Reddy's labs completes clinical studies of Rituximab biosimilar for filing in US, Europe Ruchika Sharma20 Jan 2023 3:30 PM ISTWith the successful completion of these clinical studies, Dr. Reddy’s is now preparing to file Biologics License Application (BLA) / Marketing...
Management of Myasthenia Gravis: International Consensus Guidance Dr. Kamal Kant Kohli2 Jan 2023 9:30 AM ISTMyasthenia gravis (MG) is a chronic autoimmune disorder in which antibodies destroy the communication between nerves and muscle, resulting in weakness...
